NCT01465802

Who might be able to join this trial:

• You have been diagnosed with advanced non-small cell lung cancer (NSCLC).
• For Groups 1 and 2: You have already tried at least one standard chemotherapy treatment for your advanced NSCLC, and it either stopped working or you had to stop due to side effects (you must have completed at least two cycles of that treatment).
• For Group 3: You have not yet received any systemic (whole-body) treatment for your advanced NSCLC, and your cancer has a specific genetic change known as an EGFR mutation, HER-2 mutation, or HER-2 amplification — you may also have had chemotherapy or combined chemotherapy and radiation for an earlier stage of the disease, as long as it finished more than 12 months before joining.
• You have signs of the disease present, though it does not need to be measurable on scans.
• You are reasonably active and able to care for yourself (confirm with trial site what this means for your situation).
• Your kidneys are working at an acceptable level (confirm with trial site).

Who may not be able to join:

• You have previously been treated with a drug that targets EGFR or HER receptors.
• You have had chemotherapy, radiation, biological therapy, or experimental treatments within the past 2 weeks.
• You have a condition called diffuse interstitial lung disease (a type of widespread lung scarring or inflammation).
• For Groups 1 and 2: Your only prior treatment for advanced NSCLC was an experimental therapy, with no approved chemotherapy ever received.

Important: Always verify eligibility with the trial site directly before applying.